CureVac Shares Cease Trading Following BioNTech Acquisition Finalization

The era of CureVac as a publicly traded company has concluded. The pioneering mRNA firm, headquartered in Tübingen, Germany, was formally delisted from the Nasdaq Global Market on January 16, 2026. This administrative step marks the definitive end of its independent market presence and the completion of its acquisition by fellow German biotech leader BioNTech.

BioNTech’s takeover offer successfully closed on December 18, 2025. At that time, shareholders tendered approximately 195.3 million CureVac shares, representing about 86.75% of the company’s outstanding equity. Remaining minority investors subsequently received their compensation through a mandatory squeeze-out procedure.

The legal restructuring necessary to finalize the deal was completed on January 6, 2026, at which point BioNTech became the sole owner of CureVac. The legal entity CureVac Merger B.V. succeeded CureVac N.V. through a statutory merger.

Key Transaction Details:

Should investors sell immediately? Or is it worth buying CureVac?

• Exchange Ratio: 0.05363 BioNTech American Depositary Shares (ADSs) for each CureVac share
• Premium: The offer represented an approximate 55% premium over CureVac’s three-month volume-weighted average share price as of June 2025.
• Enterprise Value: The deal valued CureVac at roughly $1.25 billion.
• Majority Support: Significant pre-commitment was secured from key investors, including dievini Hopp BioTech holding and others, who collectively controlled 36.76% of shares and had entered into tender agreements.

Leadership Transition and Integration Plans

Following the acquisition, CureVac’s previous executive team stepped down. A new board of directors for CureVac SE has been installed, comprising Prof. Ugur Sahin, Dr. Sierk Poetting, and Ramón Zapata-Gomez.

BioNTech is currently evaluating the strategic fit and product portfolio of its new subsidiary. Existing business operations will continue uninterrupted for the time being. The acquisition is viewed as a move to consolidate BioNTech’s standing within the competitive mRNA field. Specific assets of interest include CureVac’s manufacturing facility in Tübingen, which will be integrated into BioNTech’s global production network. Furthermore, CureVac’s development pipeline, particularly its oncology programs, is expected to complement BioNTech’s established cancer immunotherapy strategy.

Post-Delisting Procedures

With trading now halted, the next step involves BioNTech filing for the formal deregistration of CureVac’s shares with the U.S. Securities and Exchange Commission (SEC). Once that submission is made, public reporting obligations for the company will terminate after a standard 90-day period.